文献速递神经核医学肿瘤 PET/CT

放射性标记艾塞那肽用于β细胞成像的验证:人胰腺离体放射自显影与免疫组织化学研究

Validation of radiolabelled exendin for beta cell imaging by ex vivo autoradiography and immunohistochemistry of human pancreas.
PubMed 文献 · EJNMMI Res · 2024-10-15

研究纳入14例胰腺肿瘤成人,切除前注射111In标记艾塞那肽-4,离体放射自显影显示内分泌-外分泌摄取的比值为3.6(2.8-10.8),示踪剂蓄积与胰岛素阳性区域重叠,且该区域与GLP-1受体阳性区域重叠;4例中3例SPECT成像显示胰腺摄取。结论认为放射性标记艾塞那肽特异性蓄积于人胰岛,可用于β细胞量定量。

要点

  • 离体放射自显影显示内分泌-外分泌摄取比值为3.6(2.8-10.8)。
  • 示踪剂蓄积与胰岛素阳性区域重叠,该区域与GLP-1受体阳性区域重叠。
  • 4例中3例SPECT成像显示胰腺对放射性标记艾塞那肽的摄取。

核心结论

  • 放射性标记艾塞那肽特异性蓄积于人胰腺朗格汉斯岛。
  • 胰岛素阳性区域与GLP-1受体阳性区域明显重叠,证实了示踪剂的β细胞特异性。
  • 放射性标记艾塞那肽因此是用于人β细胞量定量的有价值显像剂,并具有一系列应用潜力,包括通过评估现有和新型糖尿病治疗对β细胞量的效应来改善糖尿病治疗。

研究设计与样本

  • 研究纳入14例胰腺肿瘤成人,在胰腺切除术前注射111In标记艾塞那肽-4。
  • 对切除胰腺组织用数字放射自显影测定示踪剂摄取的内分泌-外分泌比值,并将111In标记艾塞那肽-4的蓄积与胰岛素和GLP-1受体染色进行比较。
  • 4例受试者采集腹部SPECT/CT图像以在体内定量胰腺摄取。

主要发现

  • 示踪剂摄取主要存在于内分泌胰腺,内分泌-外分泌比值为3.6(2.8-10.8)。
  • 示踪剂蓄积与胰岛素阳性区域重叠,该区域与GLP-1受体阳性区域重叠。
  • SPECT成像显示4例参与者中3例胰腺对放射性标记艾塞那肽有摄取。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Estimation of beta cell mass is currently restricted to evaluating pancreatic tissue samples, which provides limited information. A non-invasive imaging technique that reliably quantifies beta cell mass enables monitoring of changes of beta cell mass during the progression of diabetes mellitus and may contribute to monitoring of therapy effectiveness. We assessed the specificity of radiolabelled exendin for beta cell mass quantification in humans. Fourteen adults with pancreas tumours were injected with 111In-labeled exendin-4 prior to pancreatic resection. In resected pancreas tissue, endocrine-exocrine ratios of tracer uptake were determined by digital autoradiography and accumulation of 111In-labeled exendin-4 was compared to insulin and GLP-1 receptor staining. Of four participants, abdominal single photon emission computed tomography/computed tomography (SPECT/CT) images were acquired to quantify pancreatic uptake in vivo RESULTS: Tracer uptake was predominantly present in the endocrine pancreas (endocrine-exocrine ratio: 3.6 [2.8-10.8]. Tracer accumulation showed overlap with insulin-positive regions, which overlapped with GLP-1 receptor positive areas. SPECT imaging showed pancreatic uptake of radiolabelled exendin in three participants. CONCLUSION: Radiolabelled exendin specifically accumulates in the islets of Langerhans in human pancreas tissue. The clear overlap between regions positive for insulin and the GLP-1 receptor substantiate the beta cell specificity of the tracer. Radiolabelled exendin is therefore a valuable imaging agent for human beta cell mass quantification and has the potential to be used for a range of applications, including improvement of diabetes treatment by assessment of the effects of current and novel diabetes therapies on the beta cell mass. TRIAL REGISTRATION: ClinicalTrials.gov NCT03889496, registered 26,032,019, URL https://clinicaltrials.gov/study/NCT03889496?term=NCT03889496 . CLINICALTRIALS: gov NCT04733508, registered 02022021, URL https://clinicaltrials.gov/study/NCT04733508 .

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Jansen TJP, Tokgöz S, Buitinga M, et al. Validation of radiolabelled exendin for beta cell imaging by ex vivo autoradiography and immunohistochemistry of human pancreas. EJNMMI Res. 2024. PMID: 39405026. doi:10.1186/s13550-024-01159-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。